Navigation Links
ReGear Life Sciences Closes $2.5 Million in Series A Financing Following $1M Investment by Stonewood Capital Management, Inc.
Date:3/24/2009

PITTSBURGH, March 24 /PRNewswire/ -- ReGear Life Sciences, makers of the ReBound(TM) Therapeutic Warming System, a revolutionary form of radio-frequency (RF) diathermy, today announced that it has closed a $2.5M Series A financing round following a $1M investment by Stonewood Capital Management, Inc.

"Given the current condition of the financial markets and the economy we are fortunate to have been able to attract such a great group of angel investors and close out the round with an investor as respected as Stonewood," said James (Chip) Hanlon, ReGear's President and CEO. "Participation by such a group of sophisticated investors is a testament to the potential of our products, the strength of our target markets and the abilities of our team."

ReGear received its early financial backing from the Pittsburgh Life Sciences Greenhouse and Innovation Works, opened the A round in July of 2008, and began realizing revenue late in the fourth quarter of 2008.

The funds will be used to drive growth and further expansion into the global sports medicine, physical medicine, rehabilitation, and chiropractic markets, and develop products for the home care markets. ReBound is rapidly gaining acceptance and is currently under evaluation by many major professional sports, physical therapy and rehabilitation organizations. ReBound is also being distributed by Game Ready, an industry leader in cold and compression products through a strategic alliance.

"We are delighted to be an investor in ReGear," said Stonewood Managing Director John Tippins, who has joined ReGear's board of directors. "The market for pain management products is growing every day due to the aging of the baby boomers. ReGear's diathermy technology has shown great promise in relieving pain and improving quality of life and the company is perfectly positioned to provide future therapeutic products into its target markets."

ReBound is a compact, portable, and simple-to-use therapeutic warming system that utilizes patented ReGear Diathermy(TM) technology. ReBound can be used to treat virtually any condition for which thermotherapy is indicated, including muscle spasms, joint contractures and pain associated with a variety of conditions such as osteoarthritis, soft tissue injuries, back disorders and more. No other method of thermotherapy targets deep tissue or provides sustained therapeutic warming over a broad targeted region as effectively as ReBound.

About ReGear Life Sciences

Based in Pittsburgh, PA, ReGear Life Sciences, Inc. develops and markets revolutionary products for the sports medicine, physical medicine, and rehabilitation sectors that relieve pain, accelerate recovery, and improve the quality of life. The company's flagship product, the ReBound Therapeutic Warming System, has been cleared for unattended use and delivers innovative deep tissue therapeutic warming through a patented system of comfortable body-part specific garments powered by a portable radio frequency (RF) ReGeneratorTM. For additional information, visit http://www.regearlife.com.

About Stonewood Capital Management

Stonewood Capital Management, Inc. is a Pittsburgh-based private equity firm seeking opportunities with companies with sales of $5 to $60 million as well as revenue-generating early stage companies. For further information on Stonewood, please see www.stonewoodcapital.com.


'/>"/>
SOURCE Pittsburgh Life Sciences Greenhouse
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Coventina Healthcare Enterprises, Inc. is Now ReGear Life Sciences, Inc.
2. Game Ready(TM) and ReGear Life Sciences(TM) Bring Innovative New Heat Therapy to Market
3. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
4. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
9. Cardiac Science to Present at the UBS Global Life Sciences Conference
10. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
11. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... College District , the only authorized OSHA Training Institute Education Center headquartered in ... by protecting their workers from extreme heat at their worksites. Employers with ...
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... professionals, announced today its affiliation with Tennessee Counseling Association. This new ... network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology: